Donepezil hydrochloride tablets are indicated for the treatment of dementia of the Alzheimer’s type, demonstrating efficacy in patients with mild, moderate, and severe Alzheimer’s disease. The drug’s mechanism of action involves enhancing cholinergic function by reversibly inhibiting acetylcholinesterase, increasing the concentration of acetylcholine.
Pharmacokinetic Properties of Donepezil
Pharmacokinetic studies reveal a linear dose-response over a 1-10 mg daily range, with a 70-hour elimination half-life and a mean apparent plasma clearance of 0.13 to 0.19 L/hr/kg. CYP450 isoenzymes 2D6 and 3A4 are involved in donepezil’s metabolism. Population pharmacokinetic analysis indicates peak plasma concentrations are approximately 2-fold higher with 23 mg tablets compared to 10 mg tablets. Differences in clearance values were observed among CYP2D6 genotype subgroups.
Clinical Assessment with ADAS
Clinical studies involving patients with mild to moderate Alzheimer’s disease, aged 50 to 94, utilized the ADAS-cog to assess cognitive performance, with mean scores around 26 points. The annualized rate of decline in placebo patients was approximately 2 to 6 points per year. Dosing recommendations range from 5 mg to 10 mg daily for mild to moderate Alzheimer’s disease and 10 mg to 23 mg daily for moderate to severe Alzheimer’s disease, with a starting dose of 5 mg taken in the evening.